68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer
Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Jun 7, 2024
Trial Information
Current as of August 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging technique using a special substance called 68Ga-DOTA-NI-FAPI04. This technique is designed to help doctors see tumors in patients with various types of cancer more clearly. The main goal is to find out how well this new imaging method works compared to other existing methods, such as 68Ga-FAPI or 18F-FDG PET/CT scans.
To participate in this trial, you should be an adult aged between 18 and 80 who has been diagnosed with certain types of solid tumors and has medical records confirming your diagnosis. Unfortunately, pregnant or breastfeeding women, as well as individuals with severe liver or kidney problems, cannot take part in this study. If you decide to participate, you will undergo a PET/CT scan using this new agent, which could help doctors better understand your cancer and improve future treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Various solid tumors with available histopathological findings; Signed informed consent.
- Exclusion Criteria:
- • pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.
About First Affiliated Hospital Of Fujian Medical University
The First Affiliated Hospital of Fujian Medical University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and education. As a premier sponsor of clinical trials, the hospital is committed to improving patient outcomes and contributing to medical knowledge across various specialties. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, the hospital ensures the ethical conduct and scientific rigor of its trials, fostering collaboration with global research communities. Its mission is to enhance the quality of care through evidence-based practices and to support the development of novel therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, , China
Fuzhou, Fujian, China
Patients applied
Trial Officials
Weibing Weibing, MD
Principal Investigator
First Affiliated Hospital of Fujian Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported